In this study we describe a novel interaction between the breast/ovarian tumor suppressor gene BRCA1 and the transcription factor GATA3, an interaction, which is important for normal breast differentiation. We show that the BRCA1-GATA3 interaction is important for the repression of genes associated with triple-negative and basal-like breast cancer (BLBCs) including FOXC1, and that GATA3 interacts with a C-terminal region of BRCA1. We demonstrate that FOXC1 is an essential survival factor maintaining the proliferation of BLBCs cell lines. We define the mechanistic basis of this corepression and identify the GATA3-binding site within the FOXC1 distal promoter region. We show that BRCA1 and GATA3 interact on the FOXC1 promoter and that BRCA1 requires GATA3 for recruitment to this region. This interaction requires fully functional BRCA1 as a mutant BRCA1 protein is unable to localize to the FOXC1 promoter or repress FOXC1 expression. We demonstrate that this BRCA1-GATA3 repression complex is not a FOXC1-specific phenomenon as a number of other genes associated with BLBCs such as FOXC2, CXCL1 and p-cadherin were also repressed in a similar manner. Finally, we demonstrate the importance of our findings by showing that loss of GATA3 expression or aberrant FOXC1 expression contributes to the drug resistance and epithelial-to-mesenchymal transition-like phenotypes associated with aggressive BLBCs.
Introduction
BRCA1 was identified as the first breast and ovarian cancer susceptibility gene with germ line mutations conferring a cumulative lifetime risk of up to 85% and 60% of developing breast and ovarian cancer, respectively (Miki et al., 1994) . BRCA1 is a multifunctional protein with roles in DNA damage repair, cell cycle control, transcriptional regulation and ubiquitination. It is thought to participate in transcriptional regulation at several different levels, from interacting with sequence-specific transcription factors to interactions with the RNA polymerase II complex and enzymes involved in chromatin remodeling (Anderson et al., 1998; Wang et al., 1998; Zhang et al., 1998; Bochar et al., 2000) . BRCA1 mutant breast cancers often occur at an early age of onset and are referred to as 'basal-like' (expressing the basal cytokeratins-5 and -17, (Perou et al., 1999) or 'triple negative' (estrogen receptor alpha (ERa)-and progesterone receptor-negative, low HER2 expression). They show a high incidence of accompanying p53 mutations, impaired differentiation and poor clinical outcome compared with other breast cancer subtypes. Downregulation of BRCA1 mRNA and protein expression has also been reported in approximately 30% of sporadic breast cancers (Yang et al., 2001) . Sporadic basal-like breast cancers (BLBCs) share many features with BRCA1 mutant breast cancers indicating a potential common defect, previously described as 'BRCAness' (Turner et al., 2004) . However, whilst both BRCA1 mutant and sporadic BLBCs show strong expression of basal cytokeratins, recent studies indicate that they may actually arise from aberrant luminal progenitors rather than basal stem cells as targeting BRCA1 deficiency to basal stem cells results in tumors that do not resemble BRCA1 mutant or BLBCs (Lim et al., 2009; Molyneux et al., 2010) .
The GATA family of transcription factors has fundamental roles in cell-fate specification. GATA3 is known to be a critical regulator of luminal differentiation in breast tissue, and its expression is found in luminal cells of mammary ducts and body cells of terminal end buds. Upon conditional GATA3 deletion, mice exhibited severe defects in mammary development due to failure in TEB formation during puberty (Kouros-Mehr et al., 2006) . Gata-3 deficiency results in an expansion of luminal progenitors and a concomitant block in differentiation whilst introduction of Gata-3 into a stem cell-enriched population induced maturation along the alveolar luminal lineage (Asselin-Labat et al., 2007) . In breast cancers, GATA3 is thought to be a marker of good prognosis with highest expression levels in luminal A breast cancers (Jacquemier et al., 2009; Yoon et al., 2010) . Loss of GATA3 function is associated with increased tumorigenesis and was found to be enriched in non-BRCA1/BRCA2 familial breast cancers (Arnold et al., 2010) . Somatic GATA3 mutations have also been detected in Luminal A and B subtypes suggesting that and it is thought that GATA3 may confer a generalized growth inhibitory phenotype across a number of different tumor types (Usary et al., 2004) .
FOXC1 is a member of the Forkhead Box or FOX class of transcription factors characterized by a conserved 110 amino-acid DNA-binding domain, known as a forkhead domain. FOX proteins are key regulators of diverse cellular functions including the development of many organ systems (Hannenhalli and Kaestner, 2009) . Mutations in the human FOXC1 gene underlie Axenfeld-Rieger syndrome, a disorder characterized by anterior segment malformations in the eye and glaucoma. In breast cancer, FOXC1 expression is strongly associated with the basal-like subtype of breast cancer and postulated to be a marker of poor prognosis (Ray et al., 2010; Taube et al., 2010) . FOXC1 expression in breast cancers appears to be controlled at the transcriptional level, and methylation of the FOXC1 promoter was shown to be an independent prognostic marker associated with survival (Dejeux et al., 2010) and CD44-positive (basal-like) breast tumors. Exogenous expression of FOXC1 induced a progenitor-like phenotype in differentiated mammary epithelial cells (Bloushtain-Qimron et al., 2008) .
In this study we describe a novel mechanism in which BRCA1 corepresses FOXC1 through interaction with GATA3 and show that FOXC1 is required for the proliferation/survival of BLBC cell lines. We define the GATA3 binding site within the FOXC1 distal promoter region. We show that BRCA1 and GATA3 interact on the FOXC1 promoter and that BRCA1 requires GATA3 for recruitment to this region. A mutant BRCA1 protein is unable to localize to this region or repress FOXC1. This BRCA1-GATA3 repression complex is not restricted to FOXC1 repression as other genes associated with BLBC (FOXC2, CXCL1 and p-cadherin) were also repressed in a similar manner. Finally, we demonstrate the importance of our findings by showing that FOXC1 contributes to the drug resistance and EMT (epithelial-to-mesenchymal transition)-like phenotypes associated with aggressive BLBCs.
Results

FOXC1 is a proliferation-associated gene in BLBC
To identify genes driving the proliferation of BLBCs, we designed a custom short interfering RNA (siRNA) library targeting genes previously identified as BLBCassociated genes from several published microarray data sets (Sorlie et al., 2001 (Sorlie et al., , 2003 Hu et al., 2006) . The library targeted 32 genes in total (triplicate independent siRNA oligonucleotides per gene) and was initially transfected into three BLBC cell lines; MDA-MB-468, MDA-MB-231 and HCC1937. Preliminary experiments showed six genes consistently inhibited growth in all three cell lines, PTN, CH13L2, CRABP1, CTPS1, S100A1 and FOXC1 (Figure 1a (i), (ii) and (iii) for each cell line, respectively). FOXC1, PTN and CTPS1 were further validated as being specifically associated with BLBC following real time quantitative PCR (RqPCR) comparisons of basal-like, luminal and HER2-amplified breast cancer cell lines (Figure 1b (i) , (ii) and (iii), respectively). We used two well-characterized markers of the basal (CD44) and luminal (ERa) phenotype to show that the cell line panels were representative of the different tumor subtypes (Figure 1b (iv) and (v), respectively). FOXC1 was selected for further investigation by western blotting using a panel of breast cancer cell lines representative of these three subtypes ( Figure 1c ) and was found to correlate with basal-like status. Although the general trend was increased FOXC1 mRNA and protein levels in BLBC cell lines compared with other subtypes, we did observe that mRNA levels did not necessarily correlate with protein levels in some BLBC cell lines (possibly owing to translational efficiencies between individual cell lines reflecting the heterogeneous nature of the basal-like subtype). We further demonstrated this inhibition of cell growth using three additional FOXC1 siRNA (FOXC1 si) oligonucleotides in the same cell lines (Figure 1d (i), (ii) and (iii), respectively) confirming that FOXC1 is a gene specifically associated with the proliferation and/or survival of BLBC cell lines.
BRCA1 transcriptionally regulates FOXC1 expression
Although the underlying molecular defects in BLBCs remain to be defined by the striking similarities between BRCA1 mutant and BLBCs, they suggest that loss of normal BRCA1 function may be a major contributory event. BRCA1 mutant tumors often express markers associated with normal basal/myoepithelial breast cells such as cytokeratins 5 and 17 (Perou et al., 1999; Laakso (Figure 2a (i) ) and western blotting (Figure 2a (ii) and (iii)) showed that FOXC1 levels were downregulated in both cell lines following BRCA1 reconstitution. Transient overexpression of BRCA1 in the BLBC cell line MDA-MB-157 also downregulated FOXC1 levels as shown by western blotting (Figure 2a (iv) ). BRCA1 cannot bind DNA directly and therefore requires interaction with sequence-specific transcription factors to coactivate or corepress target genes. We wanted therefore to define the mechanism through which BRCA1 transcriptionally represses FOXC1. Chromatin immunoprecipitation (ChIP)-chip analysis using a BRCA1-specific antibody identified a small region (À1277/À994 base pairs upstream of transcriptional start (TSS) of the FOXC1 gene) as a putative BRCA1 interaction site (J. Gorski, personal communication) . Transcription factor binding site prediction programs indicated that this small region contained a single GATA3 and a degenerate FOXA1/2 binding site (as shown underlined in Figure 2b ). GATA3 is a transcription factor well known to be associated with luminal differentiation in breast tissue. To demonstrate GATA3 involvement, we exogenously expressed GATA3 in three BLBC cell lines (Figure 2c (i)) and observed that GATA3 consistently repressed FOXC1 (Figure 2c (ii)). To define the minimal promoter region(s) responsible we cloned the À1277/À994 region into a luciferase reporter construct. We observed that reconstitution of BRCA1 repressed À1277/À994 FOXC1 promoter luciferase activity in MDA468 EV (empty vector)/BR (BRCA1) (Figure 2d (v)), we could demonstrate increased FOXC1 mRNA levels in MCF10A, MCF7 and T47D cells (Figure 2d (vi) ). These data therefore indicate that BRCA1 and GATA3 are both required for the repression of FOXC1 in BLBC cells.
BRCA1 interacts with and requires GATA3 to repress FOXC1
We postulated that BRCA1 might be interacting with GATA3 to target FOXC1 for repression. We were able to confirm using co-immunoprecipitation experiments (using pull downs in both orientations) that GATA3 is a novel interactor of BRCA1 (Figure 3a (i) and (ii)).
To further characterize this interaction we generated GST (glutathione S-transferase)-BRCA1 fusion proteins (representing amino acids 1-250, 304-492, 304-892 and 1503-1863 of BRCA1), overexpressed them in MCF7 cells (Figure 3a (iii)) and performed GST pull downs with the resultant lysates. GATA3 was found to interact with the C-terminus of BRCA1, predominately with amino acids 1503-1863 Figure 3a (iv)). c-Myc, which is known to interact with BRCA1 on regions amino acids 175-303 and amino acids 443-511, (Wang et al., 1998) ) was employed as a positive control for the assay and interacted specifically with GST-BRCA1 303-892.
When the GATA3 and FOXA1/2 sites within the À1277/À994 promoter region were mutated by sitedirected mutagenesis, we observed that BRCA1 could no longer repress FOXC1 promoter activity in either the HCC1937 EV/BR or the MDA468 EV/BR cell lines (Figure 3b (i) and (ii), respectively). As GATA3 and FOXA1 are known to be coexpressed in luminal breast tissue and reciprocally activate expression of each other, we postulated that FOXA1 might also reside in a complex with BRCA1. However, co-immunoprecipitation experiments indicated that FOXA1 and BRCA1 do not interact (Figure 3c ). In summary, these results demonstrate that BRCA1 and GATA3 interact and repress FOXC1 through the GATA3 binding site in the distal (À1277/À994) promoter region. Other FOX proteins such as FOXA1 may contribute to this repression mechanism we could not demonstrate a direct interaction of FOXA1 with BRCA1.
BRCA1 requires GATA3 for recruitment to the FOXC1 promoter We were therefore interested to determine whether this GATA3-BRCA1 interaction was important for recruitment of BRCA1 to the FOXC1 promoter. To investigate this, we first performed ChIP analyses of the À1277/À994 FOXC1 promoter (containing the GATA3 binding site) and demonstrated BRCA1 localization to this promoter region in MCF7 cells (Figure 4a (i) ). We could also demonstrate BRCA1 recruitment in HCC1937 cells stably reconstituted with BR but not in HCC1937 EV cells indicating that only a fully functional BRCA1 is able to target this region (Figure 4a (ii)). We then demonstrated the localization of both GATA3 and BRCA1 on the À1277/À994 FOXC1 promoter in MCF7 cells (Figure 4b ). To show the requirement of GATA3 for BRCA1 recruitment, we performed GATA3si in MCF7 cells (Figure 4c (i)) followed by ChIP assay. Knockdown of GATA3 by siRNA in MCF7 cells did not alter BRCA1 protein or mRNA levels (Figure 4c (i) and (ii)) but did result in a significant reduction of BRCA1 recruitment to the FOXC1 promoter (Figure 4c (iii) ). Together these data show that GATA3 and BRCA1 are both colocalized to the FOXC1 À1277/À994 promoter region, and that BRCA1 requires GATA3 for recruitment.
FOXC1-implications for chemotherapy responses, EMT and breast differentiation FOXC1 expression correlates with worse overall survival in BLBC patients and has been shown to have important roles in epithelial-to-mesenchymal transition (Ray et al., 2010; Taube et al., 2010) . Whilst loss of normal BRCA1 function may be a driving event in the emergence of BLBCs, the heterogeneous nature of this poorly defined subtype and the lack of sporadic BRCA1 mutations would suggest that BRCA1 dysfunction is unlikely to be consistent across all BLBCs. We wanted therefore to assess the clinical implications of aberrant FOXC1 expression independent of BRCA1 function. Current first line treatment of BLBC involves six onceweekly intravenous infusions with the DNA damaging BRCA1 and GATA3 corepress basal-like breast cancer genes D Tkocz et al chemotherapy cocktail FEC (5-Fluorouracil/Epirubicin/ Cyclophosphamide). To assess the role of FOXC1 expression in FEC chemoresistance, we used MDA-MB-468 cells (which possess low BRCA1 levels and usually show sensitivity to this type of DNA damage cocktail). We generated a number of MDA-MB-468 chemotherapy resistant clones by pulsing cells with an FEM (5-Fluorouracil/Epirubicin/Mitomycin C) DNA damage cocktail. We observed that basal levels of FOXC1 mRNA expression were increased in resistant clones compared with parental cells and further induced following FEM treatment, whilst expression remained largely unchanged in the parental cell line (Figure 5a (i) ). Correspondingly, FEM resistant clones showed an increase in IC 50 (half maximal inhibitory concentration) values of 2-10 fold (Figure 5a (ii)). In another BLBC cell line, MDA-MB-231, we used a stably integrated FOXC1 RNA shorthairpin (Figure 5a (iii) ). FOXC1 shRNA MDA-MB-231 cells showed a consistent increased sensitivity to docetaxel, a microtubule-damaging agent used in the treatment of metastatic breast cancers including BLBCs (Kouroussis et al., 1999; Campora et al., 2008; Wang et al., 2010) . IC 50 values were 2 Â 10 À9 M and 1 Â 10 À10 M for GFP shorthairpin and FOXC1shorthairpin cells, respectively (Figure 5a (iv) ). GATA3 is a well-characterized marker of luminal differentiation in breast tissue with roles in enforcing the luminal phenotype (Asselin-Labat et al., 2007). 
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We therefore wanted to assess the consequences of loss of GATA3 in luminal breast cells. GATA3 siRNA knockdown in T47D luminal breast cancer cells resulted in increased expression of a number of previously reported basal/myoepithelial markers including FOXC2, p-cadherin and CXCL1 (Rasbridge et al., 1993; Mani et al., 2007; Bierie et al., 2008) (Figure 5b (i) ). Conversely, exogenous GATA3 expression in basal-like SUM149 cells resulted in downregulation of these same markers (Figure 5b (ii) ). BLBCs often display increased EMT, resulting in increased invasive and metastatic phenotypes (Kalluri and Weinberg, 2009) . FOXC1 is a known inducer of EMT (Taube et al., 2010) and following knockdown of FOXC1 in MDA231 BLBC cells we observed a reverse in EMT-like characteristics with increased expression of E-cadherin and a decrease in the EMT markers fibronectin and vimentin (Figure 5c (i) ). We also observed by immunofluorescence an increase in E-cadherin expression and a change in cell morphology following FOXC1 si to a more 'epithelial-like' phenotype (Figure 5c (ii)). Conversely, GATA3 is known to promote ordered epithelial differentiation and reverse the EMT phenotype in breast tissue (Yan et al., 2010) . We performed GATA3si knockdown in luminal MCF7 cells (Figure 5d (i) ) resulting in a concomitant increase in the EMT-associated marker fibronectin with immunohistochemistry showing mesenchymal-like shape changes, loss of E-cadherin and a dramatic increase in fibronectin staining compared with scrambled control (SCR)siRNA (Figure 5d (ii)). Together these data implicate FOXC1 expression in chemoresistance to conventional therapies, and demonstrate the importance of GATA3 in maintaining luminal differentiation and preventing expression of basal-like genes and the accompanying EMT often observed in aggressive BLBCs.
Discussion
In this study, we have identified FOXC1 as a potentially important mediator of many of the aggressive characteristics of BLBCs. We show that FOXC1 expression is important for the proliferation/survival of BLBC cell lines, and its expression consistently correlates with the basal-like subtype of breast cancer. We show that it is transcriptionally repressed by BRCA1 through a mechanism that requires expression of GATA3. We show that GATA3 and BRCA1 interact and that this interaction is with the C-terminal end of BRCA1. We have demonstrated that GATA3 is required for BRCA1 localization on the FOXC1 distal promoter and define the GATA3 site required for FOXC1 repression. Loss of FOXC1 repression observed in BLBCs is important BRCA1 and GATA3 corepress basal-like breast cancer genes D Tkocz et al because we demonstrate a potential role for FOXC1 as a mediator of drug resistance, consistent with the correlation of FOXC1 expression with the poor response of BLBCs and triple-negative breast cancers to conventional therapy (FEC and docetaxel). Expression of FOXC1 also correlates with increased expression of EMT markers and loss of E-cadherin expression. In addition, we show that knockdown of GATA3 phenocopies FOXC1 expression, also resulting in increased expression of EMT markers. These findings implicate BRCA1 and GATA3 corepress basal-like breast cancer genes D Tkocz et al FOXC1 as an important mediator of a number of aggressive traits associated with BLBCs and may offer opportunities to develop strategies to overcome drug resistance in this aggressive breast cancer subtype. FOXC1 has been previously identified as a poor prognostic indicator in BLBCs (Ray et al., 2010) and correlated with poor overall survival in BLBC independent of other clinicopathological prognostic factors including lymph node status. The FOXC1 gene has also been reported to be hypomethylated in CD44-positive breast cancer cells and was shown to induce a progenitor-like phenotype in differentiated mammary epithelial cells (Bloushtain-Qimron et al., 2008) . Recently a mesenchymal/stromal gene expression signature including FOXC1 has been shown to relate to BLBCs, to identify bone metastasis and predict resistance to therapies (Marchini et al., 2010) . Unlike other breast cancer subtypes, BLBC does not show evidence of a dominant oncogene driving proliferation. Therefore, the strong association between BRCA1 mutation and the basal-like subtype of breast cancer probably offers the best clue to the underlying pathogenesis of this disease. However, we predict that BRCA1 dysfunction is only one of the mechanisms involved in this subtype and the 'BRCAness' phenotype does not typify all tumors of this subtype. Many pathways have been implicated in the aggressive nature of BLBCs. For example, loss of inositol polyphosphate 4-phosphatase-II signalling coincident with AKT activation (Fedele et al., 2010) , aberrant stem/progenitor cell activity through IL6 overexpression (D'Anello et al., 2010), aberrant b-catenin activation (Geyer et al., 2011; Tao et al., 2011) , aberrant Notch activation (Tao et al., 2011) , have all been implicated alongside a multitude of other potential oncogenic pathways. In this study, we decided to adopt a functional approach by constructing a focused siRNA library of genes known to be associated with BLBC. FOXC1 knockdown consistently showed profound effects on cell growth across a number of BLBC cell lines. This finding in itself is interesting as FOXC1 and FOXC2 have been implicated in metastasis rather than proliferation. Both FOXC proteins have been found to be part of the 'EMT core signature' of breast cancer that associates closely with the claudin-low and metaplastic breast cancer subtypes and correlates negatively with pathological complete response (Taube et al., 2010) .
Whilst EMT inducing transcription factors appear to predominate these breast cancer subtypes, data from our current study using BLBC cell lines would indicate that FOXC1 may have roles in addition to EMT upregulation. One possibility could be a potential role for FOXC1 in promoting cell viability and resistance to oxidative stress as previously reported in the eye (Berry et al., 2008) . Expression of FOXC1 directly correlated with the viability of human trabecular meshwork cells following oxidative stress (Berry et al., 2008) . The aberrant expression of FOXC1 in BLBCs may, therefore, represent a potential survival mechanism in a background of high oxidative damage and may explain the enhanced chemoresistance and poor survival associated with FOXC1 expression. The role of transforming growth factor (TGFb) as a mediator of EMT in many cancer types including breast cancer has been well characterized. Apart from its roles in EMT induction, TGFb has also been implicated in the ability of cancers to avoid conventional apoptotic pathways. In one such recent study, TGFb has been shown to protect breast cancer cells through a FOXC1-dependent mechanism through regulation of the pro-apoptotic protein bim (Hoshino et al., 2011) . It is likely, therefore, that the contribution of FOXC1 to the aggressive phenotypes associated with BLBC may occur through several cooperating mechanisms.
The closest homolog of FOXC1 is FOXC2 that has been shown to be required for the ability of murine mammary carcinoma cells to metastasize to the lung, and its overexpression was shown to enhance the metastatic ability of mouse mammary carcinoma cells (Mani et al., 2007) . FOXC2 expression was shown to be induced in EMT triggered by a number of signals, including TGFb1 and several EMT-inducing transcription factors, such as Snail, Twist and Goosecoid (Mani et al., 2007) . Interestingly, FOXC2 expression correlates significantly with highly aggressive BLBCs, in a manner similar to FOXC1. Given our findings, it is therefore tempting to speculate that the expression levels of both FOXC proteins are aberrantly elevated through a common dysfunction in transcriptional control, namely loss of BRCA1 function and BRCA1-GATA3 corepression. (ii) Bright field images of MCF7 cells following treatment with SCR and GATA3si (top panels) and immunofluorescence staining for E-cadherin (middle panels) and fibronectin (bottom panels). *Po0.05; **Po0.01; ***Po0.001.
BRCA1 and GATA3 corepress basal-like breast cancer genes D Tkocz et al GATA3 has been known for some time to be a good prognosis indicator in breast cancers with higher GATA3 levels predicting for better prognosis in ERa-positive breast cancers (Yoon et al., 2010) . GATA3 has been shown to inhibit breast cancer metastasis through the reversal of epithelial-mesenchymal transition (Yan et al., 2010) . GATA3 has also been reported to be coexpressed with another good prognosis indicator, FOXA1, in luminal A breast cancers and the expression of both proteins are known to predict for good prognosis (Ademuyiwa et al., 2010) . There is also evidence that FOXA1 may also predict for better clinical outcome in ERa-negative breast tumours (Albergaria et al., 2009) . GATA3 is also known to be required for specification and maintenance of the luminal phenotype in breast tissue (Kouros-Mehr et al., 2006 . In this study, we show for the first time a physical interaction between BRCA1 and GATA3 and a requirement for GATA3 in controlling BRCA1 transcriptional targets. We postulate that BRCA1 may therefore control the growth and differentiation of primitive breast cells by targeting GATA3 responsive genes. We could not detect FOXA1 interacting with BRCA1 but we suspect that the expression of FOXA1 may lie transcriptionally downstream of BRCA1-GATA3. Indeed, FOXA1 has been shown to be transcriptionally regulated by GATA3 (Kouros-Mehr et al., 2006) . The importance of GATA3 expression in repressing tumorigenesis is highlighted in a previous study, which showed that exogenous GATA3 expression inhibited the growth and pulmonary metastatic activity (both phenotypes associated with FOXC-expressing BLBCs) of a highly aggressive breast cancer cell line (Dydensborg et al., 2009) . The requirement of GATA3 for the ability of BRCA1 to repress basal-like genes, would therefore, explain why BRCA1 mutant breast tumors show elevated expression of basal-like markers such as FOXC1 and FOXC2. The recent advances in the use of poly(ADPribose) polymerase (PARP) inhibitors to target DNA repair defects in breast and ovarian cancers (Farmer et al., 2005) has given us a good example of how increasing our knowledge of the underlying pathology of certain tumor types (such as BRCA1 and BRCA2 mutant breast cancers) may be exploited therapeutically. However, it is currently unclear given the heterogeneity of BLBCs whether the use of PARP inhibitors will be effective in this disease.
In summary, we have for the first time identified GATA3 as a BRCA1 interacting protein responsible for the repression of a number of BRCA1 target genes including the basally restricted transcription factor FOXC1. We believe this is an important finding as many of the features of highly aggressive BLBCs (high proliferation rates, chemoresistance and EMT-like phenotypes) may be due to disrupted BRCA1-GATA3 repression accompanied by aberrant FOXC1 overexpression. It is clear that we currently lack a detailed understanding of the underlying biology of how BRCA1 dysfunction leads to the emergence of BLBCs. We also require a greater understanding on how BLBCs arise in the absence of BRCA1 dysfunction and how we can predict which tumors will respond to DNA damagebased or PARP1 inhibition therapy and those which will not. However, we predict that the identification of BRCA1-GATA3 coregulated targets will prove valuable in developing novel therapeutic strategies against a disease with no current targeted therapy.
Materials and methods
Cell lines HCC1937 and MDA468 cell lines reconstituted with BRCA1 and HME1 cell lines were maintained as previously described (Buckley et al., 2011) . All other cell lines were maintained as previously described (Neve et al., 2006) in a humidified incubator at 37 1C in 5% (v/v) CO 2 /air. All cell lines used in this study have been directly sourced from commercial cell line suppliers that will verify the authenticity and absence of cross-contamination for each cell line (Health Protection Agency, (Middlesex, UK) LGC Standards, ATCC). Passage numbers (post-thawing) was routinely recorded for each cell line population during culture, and experiments were performed within a maximal number of passages (o20). MDA231 FOXC1 shorthairpin cell lines were a kind gift from Fred Berry (Department of Medical Genetics, University of Alberta). FEM-resistant MDA468 clones were generated following treatment of MDA-MB-486 cells with six cycles of 1 mM FEM.
RNA preparation and cDNA synthesis RNA was extracted from cells using RNA STAT-60 reagent (Tel-Test Inc, Friendswood, TX, USA) according to manufacturer's instructions. RNA was then reverse transcribed using the Transcriptor First Stand cDNA synthesis kit (Roche, Burgess Hill, UK) according to manufacturer's instructions.
Real-time quantitative PCR
Quantitative real time PCR was carried out on the Opticon 2 cycler (Bio-Rad, Hemel Hempstead, UK) using Syber green (Roche), according to manufacturer's instructions. Primer sequences for RqPCR are listed in Supplementary data, materials and methods.
Western blot analysis and antibodies Protein lysates were extracted in EDTA lysis buffer (0.25 M NaCl 0.1% IGEPAL, 0.25 M HEPES ((4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 5 M EDTA, 0.5 M DTT), separated by SDS-polyacrylamide gel electtrophoresis and transferred to polyvinylidene difluoride membrane followed by immunoblotting. Antibodies; FOXC1: Abcam (Cambridge, UK) (ab5079), BRCA1: D9 Santa Cruz (sc-6954), GATA3: HG3-35 Santa Cruz (Santa Cruz, CA, USA) (sc-269), FOXA1: Santa Cruz H-120 (sc-22841), b-tubulin: TUB2.1 Sigma (Gillingham, UK), E-cadherin: BD transduction laboratories (Franklin Lakes, NJ, USA), vimentin: RV202 Abcam. Mouse anti-human fibronectin antibody was a kind gift from Professor Philip Rudland (University of Liverpool). BRCA1 and GATA3 were immunoprecipitated with Ab4 SD118 Calbiochem (Darmstadt, Germany) and HG3-35 Santa Cruz, respectively. IgG isotype controls were purchased from Dako Cytomation (Cambridgeshire, UK).
Short interfering RNA experiments
Cells were transfected using oligofectamine reagent (Invitrogen, Paisley, UK) according to manufacturer's instructions. Protein or RNA was collected from cells 72 h following treatment with 100 nM siRNA. SiRNA primer sequences are listed in Supplementary data, materials and methods.
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